The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
Abstract
Liver transplantation is the only effective treatment for hereditary tyrosinaemia type I (McKusick 276700). We have treated one acute and four subacute-chronic cases with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), to prevent the formation of maleylacetoacetate and fumarylacetoacetate and their saturated derivatives. The oral daily dose was 0.1-0.6 mg/kg. The excretion of succinylacetoacetate and succinylacetone decreased from 15-103 mmol/mol creatinine to the detection limit or slightly above (ie, to 20-150 mumol/mol creatinine). The concentration of succinylacetone in plasma decreased from 5.8-43 mumol/l to the detection limit (0.1 mumol/l) over 2-5 months of treatment. The almost complete inhibition of porphobilinogen synthase in erythrocytes was abolished and the excretion of 5-aminolevulinate decreased to within or slightly above the reference range. The concentration of alpha-fetoprotein decreased in four patients to 1.3-7.5% of initially high values over 6-8 months. Improved liver function was reflected by normal concentrations of prothrombin complex and in decreased activities of alkaline phosphatase and gamma-glutamyltransferase in serum. Computed tomography revealed regression of hepatic abnormalities in three patients. One patient developed rickets 6 months before treatment and had excreted high concentrations of markers of tubular dysfunction--after 3 weeks of treatmen…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase, an enzyme that is upstream of fumarylacetoacetase (Figure 1).”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [3]
In the citing paper
“As a result the flux through the pathway is markedly reduced and in most patients there is a rapid decrease in the concentrations of succinylacetone, an increase in tyrosine and a clear clinical improvement.”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [3]
In the citing paper
“Nitisinone is a compound that has revolutionised the management of tyrosinaemia type 1 [3,4].”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [3]
In the citing paper
“and its presence is diagnostic for the disease (2, 8, 9).”
From Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1 (2001) · cites this paper as [9]
In the citing paper
“Elevation of SA above normal levels (in serum, urine, and/or amniotic fluid) is the specific diagnostic indicator for HT1 (6, 7, 9, 37, 38).”
From Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1 (2001) · cites this paper as [9]
Citations
Cites
The occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G., Larochelle, J., Lambert, M., Michaud, J., Grenier, A., Ogier, H., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 232
Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.
(1990) · Europe PMC (PubMed Central) · Cited by 163
Gentz, J., JAGENBURG, R., & Zetterström, R. H. (1965) · The Journal of Pediatrics · doi:10.1016/s0022-3476(65)80002-6 · Cited by 129
Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid.
Tschudy, D. P., Hess, R. A., & Frykholm, B. C. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68717-x · Cited by 113
Hereditary tyrosinemia type I--an overview.
Kvittingen, E. A. (1986) · PubMed · Cited by 109
Dm, D. (1989) · Medical Entomology and Zoology · Cited by 96
Grenier, A., Lescault, A., Laberge, C., Gagné, R., & Marner, O. (1982) · Clinica Chimica Acta · doi:10.1016/0009-8981(82)90117-6 · Cited by 73
Excretion of δ-aminolevulinic acid in hereditary tyrosinemia
Gentz, J., Johansson, S., Lindblad, B., Lindstedt, S., & Zetterström, R. (1969) · Clinica Chimica Acta · doi:10.1016/0009-8981(69)90040-0 · Cited by 69
Self-citationEndo, F., Kitano, A., Uehara, I., Nagata, N., Matsuda, I., Shinka, T., Kuhara, T., & Matsumoto, I. (1983) · Pediatric Research · doi:10.1203/00006450-198302000-00002 · Cited by 59
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Natural History of Alkaptonuria
Phornphutkul, C., Introne, W. J., Perry, M. B., Bernardini, I., Murphey, M. D., Fitzpatrick, D. L., Anderson, P. D., Huizing, M., Anikster, Y., Gerber, L. H., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021736 · Cited by 665
Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes.
Overturf, K., Al-Dhalimy, M., Ou, C. N., Finegold, M. J., & Grompe, M. (1997) · Europe PMC (PubMed Central) · Cited by 597
Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549
2-Oxoglutarate-Dependent Oxygenases
Islam, M. S., Leissing, T. M., Chowdhury, R., Hopkinson, R. J., & Schofield, C. J. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044724 · Cited by 472
Metadata
- Authors
- LINDSTEDT, S.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Corresponding author
- LINDSTEDT, S
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1992-10
- Volume
- 340
- Issue
- 8823
- Pages
- 813-817
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2045299448
- Cited by
- 631
- References
- 19
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 12 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 24 · 2019: 28 · 2018: 19 · 2017: 40 · 2016: 19 · 2015: 24 · 2014: 21 · 2013: 20 · 2012: 17
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- NTBC, succinylacetone, delta-aminolevulinic acid dehydratase, 5-aminolevulinic acid, alpha-fetoprotein, cirrhosis prevention, liver cancer risk, liver transplantation alternatives, rickets, tubular dysfunction
- MeSH terms
- Acetoacetates, alpha-Fetoproteins, Amino Acid Metabolism, Inborn Errors, Aminolevulinic Acid, Porphobilinogen Synthase, Child, Child, Preschool, Cyclohexanones, Erythrocytes, Heptanoates, Humans, Infant, Kidney Tubules, Liver, Nitrobenzoates, Phenylalanine, Phosphates, Proteinuria, Tyrosine, 4-Hydroxyphenylpyruvate Dioxygenase, Hydroxybenzoates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. https://app.cochat.ai/papers/10.1016/0140-6736(92)92685-9
- The paper
- LINDSTEDT, S. (1992). Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. The Lancet. https://doi.org/10.1016/0140-6736(92)92685-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.